Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Why It Matters

The high response rates in heavily pretreated ovarian and endometrial cancers position ZW191 as a potential best‑in‑class therapy, expanding options where few exist. Successful early data also validates Zymeworks' ADC platform, strengthening its appeal to investors and strategic partners.

Key Takeaways

• ZW191 achieved 61% cORR in ovarian cancer at 6.4‑9.6 mg/kg.
• Median progression‑free survival reached 7.6 months across cohorts.
• Grade ≥ 3 adverse events occurred in 55% of patients, manageable.
• Responses observed regardless of folate receptor α expression levels.

Pulse Analysis

Antibody‑drug conjugates (ADCs) have emerged as a transformative class of oncology therapeutics, marrying the specificity of monoclonal antibodies with potent cytotoxic payloads. Zymeworks’ ZW191 targets folate receptor‑α (FRα), a protein overexpressed in roughly three‑quarters of high‑grade serous ovarian cancers and more than half of endometrial tumors. By delivering a novel topoisomerase‑1 inhibitor directly into FRα‑positive cells, the ADC aims to overcome the limited efficacy and systemic toxicity of conventional chemotherapy, addressing a clear unmet need in platinum‑resistant gynecologic malignancies.

The Phase 1 dose‑escalation data presented at AACR 2026 reveal a striking 61% confirmed objective response rate in ovarian cancer patients treated at 6.4‑9.6 mg/kg, with disease control observed in virtually all participants. Median progression‑free survival of 7.6 months suggests durable benefit, while the rapid median time to response of 1.4 months underscores the therapy’s potency. Safety signals were acceptable for an early‑stage trial; grade ≥ 3 adverse events—primarily neutropenia, anemia, and thrombocytopenia—affected 55% of patients, and only one grade 5 event occurred, unrelated to treatment. These findings indicate a favorable therapeutic window that justifies advancing to the dose‑optimization phase.

For Zymeworks, the data serve as a pivotal proof‑of‑concept for its ADC platform, potentially unlocking a pipeline of FRα‑directed candidates across multiple tumor types, including lung adenocarcinoma where FRα prevalence is also high. Positive early‑stage outcomes can accelerate partnership discussions, boost market confidence, and improve the company’s cash‑flow outlook as it leverages licensed assets like Ziihera. As the oncology community seeks novel options for patients with limited alternatives, ZW191’s progression could reshape treatment algorithms and reinforce the strategic value of ADC technology in the broader biopharma landscape.